Prenetics Global Q4 revenue surges 457%

Prenetics Global

18/02/2026 14:21

Overview

Consumer health sciences firm's Q4 revenue surged 457% YoY to $36.6 mln

Company completed strategic divestitures, boosting liquidity to $171 mln

IM8 brand drove FY2025 revenue growth, achieving $120 mln ARR milestone

Outlook

Prenetics reaffirms 2026 IM8 revenue guidance of $180 mln to $200 mln

Company targets $250 mln to $300 mln in ARR for IM8 by end of 2026

Prenetics expects adjusted EBITDA loss of $16 mln to $20 mln for 2026

Result Drivers

IM8 PERFORMANCE - IM8 was the primary growth driver, achieving $120 mln in ARR within 12 months and contributing $60.1 mln in FY2025 revenue

STRATEGIC TRANSFORMATION - Prenetics completed divestitures, including ACT Genomics and Europa, to focus on IM8 and strengthen liquidity

GLOBAL EXPANSION - IM8's revenue growth was diversified across geographies, with over 60% of revenue generated outside the U.S.

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
$36.60 mln
Q4 EPS
-$4.15
Q4 Gross Margin
60.00%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Prenetics Global Ltd is $31.00, about 42.6% above its February 17 closing price of $21.74

Press Release: ID:nGNXbLb31y

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)